Mersana Therapeutics Stock Performance
| MRSN Stock | USD 3.21 0.06 1.90% |
Mersana Therapeutics has a performance score of 2 on a scale of 0 to 100. The company secures a Beta (Market Risk) of 2.39, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Mersana Therapeutics will likely underperform. Mersana Therapeutics right now secures a risk of 5.37%. Please verify Mersana Therapeutics value at risk, as well as the relationship between the skewness and day median price , to decide if Mersana Therapeutics will be following its current price movements.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Mersana Therapeutics are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating basic indicators, Mersana Therapeutics may actually be approaching a critical reversion point that can send shares even higher in May 2024. ...more
Actual Historical Performance (%)
One Day Return 3.97 | Five Day Return (4.80) | Year To Date Return 44.27 | Ten Year Return (76.61) | All Time Return (76.61) |
1 | Should You Buy Mersana Therapeutics Inc Stock on Thursday - InvestorsObserver | 02/08/2024 |
2 | Mersana Therapeutics Full Year 2023 Earnings Revenues Disappoint | 02/29/2024 |
3 | Mersana Therapeutics Upgraded to Outperform at Wedbush | 03/01/2024 |
4 | Mersana Therapeutics PT Raised to 5.00 | 03/04/2024 |
5 | Acquisition by Anna Protopapas of 16750 shares of Mersana Therapeutics subject to Rule 16b-3 | 03/05/2024 |
6 | Mersana Therapeutics, Inc. Receives Average Recommendation of Moderate Buy from Analysts | 03/07/2024 |
7 | Mersana Therapeutics Upgraded to Neutral at JPMorgan Chase Co. - Defense World | 03/20/2024 |
8 | Acquisition by Lawrence Alleva of 96 shares of Mersana Therapeutics at 4.42 subject to Rule 16b-3 | 04/01/2024 |
9 | Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 | 04/04/2024 |
| Begin Period Cash Flow | 128.9 M |
Mersana |
Mersana Therapeutics Relative Risk vs. Return Landscape
If you would invest 313.00 in Mersana Therapeutics on January 24, 2024 and sell it today you would earn a total of 2.00 from holding Mersana Therapeutics or generate 0.64% return on investment over 90 days. Mersana Therapeutics is currently generating 0.1497% in daily expected returns and assumes 5.3691% risk (volatility on return distribution) over the 90 days horizon. In different words, 47% of stocks are less volatile than Mersana, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Mersana Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Mersana Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Mersana Therapeutics, and traders can use it to determine the average amount a Mersana Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0279
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | MRSN | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.37 actual daily | 47 53% of assets are more volatile |
Expected Return
| 0.15 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Mersana Therapeutics is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Mersana Therapeutics by adding it to a well-diversified portfolio.
Mersana Therapeutics Fundamentals Growth
Mersana Stock prices reflect investors' perceptions of the future prospects and financial health of Mersana Therapeutics, and Mersana Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Mersana Stock performance.
| Return On Equity | -2.66 | ||||
| Return On Asset | -0.38 | ||||
| Operating Margin | (1.96) % | ||||
| Current Valuation | 206.85 M | ||||
| Shares Outstanding | 121.3 M | ||||
| Price To Earning | (0.98) X | ||||
| Price To Book | 12.49 X | ||||
| Price To Sales | 12.54 X | ||||
| Revenue | 36.85 M | ||||
| Gross Profit | (146.8 M) | ||||
| EBITDA | (169.44 M) | ||||
| Net Income | (171.67 M) | ||||
| Cash And Equivalents | 225.13 M | ||||
| Cash Per Share | 2.32 X | ||||
| Total Debt | 33.83 M | ||||
| Debt To Equity | 0.28 % | ||||
| Current Ratio | 3.32 X | ||||
| Book Value Per Share | 0.31 X | ||||
| Cash Flow From Operations | (168.88 M) | ||||
| Earnings Per Share | (1.48) X | ||||
| Market Capitalization | 382.1 M | ||||
| Total Asset | 226.06 M | ||||
| Retained Earnings | (826.36 M) | ||||
| Working Capital | 150.42 M | ||||
| Current Asset | 71.4 M | ||||
| Current Liabilities | 51.32 M | ||||
About Mersana Therapeutics Performance
To evaluate Mersana Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Mersana Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Mersana Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Mersana Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Mersana's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 0.00 | 0.00 | |
| Return On Tangible Assets | (0.76) | (0.80) | |
| Return On Capital Employed | (1.05) | (1.11) | |
| Return On Assets | (0.76) | (0.80) | |
| Return On Equity | (4.65) | (4.42) |
Things to note about Mersana Therapeutics performance evaluation
Checking the ongoing alerts about Mersana Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Mersana Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Mersana Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 36.85 M. Net Loss for the year was (171.67 M) with loss before overhead, payroll, taxes, and interest of (146.8 M). | |
| Mersana Therapeutics currently holds about 225.13 M in cash with (168.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.32. | |
| Mersana Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 95.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 |
- Analyzing Mersana Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Mersana Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Mersana Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Mersana Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Mersana Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Mersana Therapeutics' stock. These opinions can provide insight into Mersana Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mersana Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Complementary Tools for Mersana Stock analysis
When running Mersana Therapeutics' price analysis, check to measure Mersana Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mersana Therapeutics is operating at the current time. Most of Mersana Therapeutics' value examination focuses on studying past and present price action to predict the probability of Mersana Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mersana Therapeutics' price. Additionally, you may evaluate how the addition of Mersana Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |
Is Mersana Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mersana Therapeutics. If investors know Mersana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mersana Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.48) | Revenue Per Share 0.317 | Quarterly Revenue Growth (0.27) | Return On Assets (0.38) | Return On Equity (2.66) |
The market value of Mersana Therapeutics is measured differently than its book value, which is the value of Mersana that is recorded on the company's balance sheet. Investors also form their own opinion of Mersana Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mersana Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mersana Therapeutics' market value can be influenced by many factors that don't directly affect Mersana Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mersana Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mersana Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mersana Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.